📰 Psychedelics News
Curated updates on microdosing, research, policy, and community.
Filters
Q4’25 Psychedelic Lobbying Update
Each quarter, we provide a look at federal lobbying disclosures by psychedelic drug developers and nonprofits. Here, we share our analysis of the latest developments for our Pα+ subscribers.
Psychedelics and Weight Loss
Oli Genn-Bash argues that while traditional weight loss focuses on calories, exercise, and willpower, psychedelics may indirectly support healthier habits and self-relationship by rewiring the brain, addressing trauma...
Ketamine Assisted Psychotherapy for Couples
Enamory is hosting a training for therapists interested in adding KAP to their couples therapy work. Learn more here. Some of the Enamory team were recently guests on the Psychedelics Today podcast. Listen here. The p...
Psychedelics, Depth, and the Human Psyche: Psychedelics, Depth, and the Human Psyche
Join us for a full-day virtual seminar on March 15th, where leading experts converge to explore the transformative intersection of psychedelic medicine, depth psychology, and collective healing. This immersive seminar...
What Happens to Mushroom Science in a Post-Truth Internet?
It's all happening: Harmful mushroom advice, AI hallucinations, and the collapse of online trust. [...] Read More... The post What Happens to Mushroom Science in a Post-Truth Internet? appeared first on DoubleBlind Mag.
What Ibogaine Can (and Can’t) Do: A Real Recovery Story
By the time Laura Shapiro found ibogaine, nothing else had worked — she was completely out of options.
Psychedelics and Polysubstance Use: What to Avoid
Psychedelics are often mixed with other substances at parties, producing unpredictable and sometimes synergistic or risky effects. Because scientific research on such combinations is limited, harm-reduction knowledge ...
Dr. Chandra Khalifian and Dr. Kayla Knopp: Enamory, Ketamine and Couples Therapy
Enamory is a clinical practice, training institute, and nonprofit research organization focused on psychedelic assisted couples therapy. In this episode, clinical psychologists Chandra Khalifian and Kayla Knopp discus...
The Future of Whole Brain Emulation
Whole brain emulation without the sci-fi, by PsyMed’s Danny Carbonero
Taking the Helm at Helus: A Brief Q&A With New CEO Michael Cola
Psychedelic Alpha’s Josh Hardman speaks with newly appointed Helus Pharma CEO Michael Cola in a brief Q&A on execution, regulatory rigor, and scaling serotonergic CNS medicines.
The Psychedelic Practitioner Issue 3: Dosing
The Psychedelic Practitioner by Psychedelic Alpha is a new publication designed specifically for therapists, clinicians, facilitators, and other professionals working with—or preparing to work with—psychedelic therapi...
Dreaming While Under: 5 Questions with anesthesiologist Harrison Shong-Wen Chow
Chow discusses how dreams during surgery have relieved trauma symptoms.
Two New Studies Are Rewriting the Rules of Psychedelic Drug Development
For much of the last decade, psychedelic medicine has been driven by clinical outcomes first and mechanistic explanations second. Promising results in depression, anxiety, and trauma propelled compounds like psilocybi...
Members of the “Psychedelic Elite” Appear in the Epstein Files
PLUS, psychedelics on capitol hill, Lykos Therapeutics, and Right to Try. [...] Read More... The post Members of the “Psychedelic Elite” Appear in the Epstein Files appeared first on DoubleBlind Mag.
Psychedelics and Mark Fisher’s Theory of the Weird
In his book The Weird and the Eerie, cultural theorist Mark Fisher analyses the concept of the ‘weird’. Sam Woolfe applies Fisher’s analysis to psychedelic states. The post Psychedelics and Mark Fisher’s Theory of the...